

Carcinosarcoma

Uterine corpus

Morphology • Clonality • Prognostic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Learning objectives

- Recognize malignant epithelial and mesenchymal components in the same uterine tumor.
- Relate the molecular evidence for clonality to the current carcinoma-oriented model.
- Differentiate carcinosarcoma from adenosarcoma, leiomyosarcoma and other high-grade malignancies.
- Interpret invasion, stage and heterologous differentiation as prognostic information.

Carcinosarcoma is a biphasic malignant tumor

Malignant epithelial component

- Usually adenocarcinomatous
- Often high grade

Malignant mesenchymal component

- Sarcomatous differentiation
- Homologous or heterologous

Both elements are malignant: The biphasic appearance is the defining feature.

The two components are parts of one tumor



Shared molecular drivers support common ancestry rather than two unrelated adjacent neoplasms.

Place of origin and clinical context

- The presentation addresses carcinosarcoma of the uterine corpus.
- It is discussed alongside aggressive endometrial carcinomas.
- Both primary morphology and metastatic distribution link it to the carcinoma family.

Historical terminology versus current concept

Historical designation


- Malignant mixed Müllerian tumor
- Emphasized morphologic duality

Biologic interpretation

- Metaplastic / biphasic carcinoma concept
- Supported by shared driver alterations

The historical name remains familiar; The contemporary model emphasizes epithelial lineage.

A postmenopausal presentation prompts evaluation




Bleeding is a reported typical presentation, not a disease-specific diagnostic sign.

Bleeding is a symptom, not a histologic diagnosis

- Carcinosarcoma commonly presents with uterine bleeding.
- Other endometrial lesions may present in the same way.
- The diagnosis requires tissue demonstrating appropriate malignant components.

Gross appearance: A bulky uterine mass



Shape and site raise suspicion; Gross appearance alone cannot determine the biphasic histology.

The cavity–myometrium interface matters

Endometrium / cavity interface

Myometrium

Outer uterine wall

Invasion is evaluated across the wall—not inferred from tumor size alone.

Schematic—not to anatomic scale

Polypoid growth can become clinically visible

- The tumor may project into the cavity as a polypoid lesion.
- Some tumors protrude through the cervical os.
- A polypoid configuration does not imply benign biology.

What must be recognized microscopically?

Carcinomatous tissue

- Overt malignant epithelial cytology
- Glandular, papillary or solid patterns

Sarcomatous tissue

- Overt malignant mesenchymal morphology
- Spindle, pleomorphic or differentiated sarcoma

Morphology drives diagnosis; Immunostains are adjuncts.

Epithelial component: Common patterns

Poorly differentiated endometrioid

- Endometrioid gland-forming lineage
- May be high-grade / poorly formed

Serous-like carcinoma

- High-grade serous phenotype
- Cytologically malignant epithelium

These are examples, not two mandatory coexisting epithelial subtypes.

Clear cell–type epithelium can also occur

- Clear cell carcinoma among possible epithelial areas.
- The histologic carcinoma component may be heterogeneous.
- Recognition of carcinoma does not remove the need to search for sarcoma.

An epithelial pattern may dominate a section

- A section may show mostly adenocarcinoma.
- The biphasic component can be focal or separated spatially.
- Broader sampling may change a provisional high-grade carcinoma diagnosis.

Sarcomatous component: Two broad categories

Homologous

- Differentiation resembling uterine mesenchymal tissues
- Examples: Stromal sarcoma, leiomyosarcoma-like

Heterologous

- Differentiation resembling tissues not native to the uterus
- Examples: Rhabdomyosarcoma, chondrosarcoma

This distinction refers to tissue differentiation—not to clonal independence.

Homologous mesenchymal differentiation

- Can resemble malignant endometrial stroma.
- Can resemble a malignant smooth-muscle tumor.
- The adjacent carcinomatous component establishes carcinosarcoma.

Heterologous differentiation is an adverse feature

- The sarcomatous component may recapitulate nonuterine tissue types.
- Heterologous components with poorer prognosis.
- This information supplements—not replaces—stage and invasion assessment.

Rhabdomyosarcomatous differentiation

Morphologic identity

- Malignant cells with skeletal-muscle lineage
- A heterologous sarcomatous form

Diagnostic inference

- Demonstrate bona fide rhabdomyoblastic differentiation
- Confirm the accompanying carcinoma

Myogenin/MyoD1 may support rhabdomyoblastic differentiation when required.

Chondrosarcomatous differentiation

Morphologic identity

- Malignant cartilage-forming component
- Example of heterologous tissue

Diagnostic inference


- Examine cytologic malignancy within chondroid areas
- Distinguish true sarcoma from incidental cartilage

Carcinoma plus malignant chondroid differentiation supports carcinosarcoma.

Other heterologous components described

- Malignant differentiation that resembles adipose tissue or bone.
- Identity of a heterologous component requires more than a tissue-like appearance.
- Careful morphologic interpretation is essential before assigning lineage.

Two components may be intimately admixed




■ Carcinoma-rich

■ Sarcoma-rich

Component-distribution schematic (not histology)

Original component-distribution schematic: Intermixed gray and blue regions, not a histologic specimen.

Two components may be spatially distinct



■ Carcinoma-rich

■ Sarcoma-rich

Component-distribution schematic (not histology)

A single sampled block may capture only one region of a heterogeneous tumor.

Sampling can uncover otherwise missed differentiation




- Tumor is heterogeneous
- Biopsy samples only part
- Additional tissue may reveal second component

Practical inference from source-described spatial heterogeneity; No numerical block requirement implied.

A limited biopsy may underrepresent a component

- Carcinoma-only tissue cannot demonstrate the sarcomatous component.
- Sarcoma-only tissue may obscure the epithelial lineage.
- If clinically suspected, consider the sampling limitation in the pathology interpretation.

Metastases typically favor the epithelial component




Metastatic deposits usually contain only the epithelial component.

An epithelial-only metastasis is not contradictory

- The metastatic site need not reproduce the biphasic primary appearance.
- An epithelial-only nodal deposit can originate from a uterine carcinosarcoma.
- Primary tumor morphology and clinical linkage remain essential.

Shared drivers support monoclonality



Clonal origin is supported by genetics; The precise differentiation mechanism is unresolved.

PTEN is one illustrative shared driver

- PTEN among altered genes found in carcinosarcoma.
- PTEN also features in endometrial carcinoma pathogenesis.
- Its presence is evidence of molecular overlap, not a specific stand-alone diagnostic test.

PIK3CA links the tumor to carcinoma biology

- PIK3CA is another gene highlighted in the source.
- Its alteration overlaps with the genetic landscape of endometrial carcinoma.
- A listed driver gene is not present in every individual tumor.

TP53 provides a major molecular connection

- TP53 alterations are common in aggressive endometrial carcinomas.
- Most carcinosarcomas fall in a copy-number-high/TP53-mutated molecular group.
- Do not assume TP53 abnormality in every carcinosarcoma.

Genetic resemblance is asymmetrical

Carcinoma-associated alterations


- PTEN, TP53, PIK3CA listed by Robbins
- Shared across tumor components

Typical sarcoma-associated alterations

- Absence of changes typical of sarcomas
- Supports carcinoma-related evolution

This is a lineage argument, not a rule that no mesenchymal alterations can ever exist.

Proposed sarcomatous conversion



Conceptual model; Specific conversion mechanism remains unproven.

Epigenetic regulation is a hypothesis

- Robbins suggests abnormal epigenetic regulation may contribute.
- The molecular steps behind sarcomatous transformation are currently uncertain.
- Avoid presenting a single pathway as fully established.

Clonality and conversion answer different questions

Clonality

- Do components share a founding cancer clone?
- Source evidence: Shared driver mutations

Conversion mechanism

- How does a carcinoma-derived clone acquire sarcomatous identity?
- Specific regulatory steps remain unclear

Strong support for shared origin does not establish each mechanistic step.

Most carcinosarcomas map to copy-number-high disease

- The copy-number-high/TP53-mutated molecular subtype.
- This places most cases close to aggressive endometrial carcinoma biology.
- A molecular-class label should not replace full morphologic diagnosis.

Molecular groups: Where does carcinosarcoma fit?

Molecular group	Robbins context
POLE-ultramutated	Endometrial carcinoma class; Not the typical UCS pattern
MMR-deficient/MSI	Endometrial carcinoma class; Not the predominant UCS group
Copy-number low / NSMP	Often associated with endometrioid carcinoma
Copy-number high / TP53	Dominant group described for carcinosarcoma

Invasion carries direct prognostic information


- Depth of invasion is a principal prognostic factor.
- Report whether the tumor infiltrates the myometrium.
- Gross appearance alone cannot reliably establish microscopic invasion depth.

Depth of myometrial invasion: Schematic

Confined to endometrium



Invades myometrium



Extends past outer wall



Conceptual growth-depth illustration; Not a staging substitute.

Anatomic stage is a leading determinant of outcome

- Stage summarizes local extension and spread beyond the uterus.
- Stage, along with depth, as central prognostic determinants.
- Discuss stage with the specific staging-system year.

Heterologous component: A separate risk variable

Major drivers

- Disease stage
- Depth of invasion

Additional adverse finding

- Heterologous sarcomatous differentiation
- Associated with worse outcome

Histologic differentiation is not an alternative to staging.

Interpreting the reported high-stage survival

- An overall 5-year survival of 25–30% for high-stage disease.
- This estimate applies to the referenced high-stage group, not every case.
- Population outcomes must not be used to predict one individual's course.

From gross tumor to risk assessment



Full risk interpretation depends on anatomic stage and the relevant multidisciplinary context.

Important uterine biphasic differential

Feature	Carcinosarcoma	Adenosarcoma
Glandular epithelium	Malignant	Usually benign
Stromal compartment	Malignant sarcoma	Malignant stroma
Usual teaching clue	Two overtly malignant components	Benign glands with malignant stroma
Polypoid uterine lesion	Possible	Possible

Malignancy of the epithelium is discriminating

- Adenosarcoma has benign but architecturally abnormal glands.
- Carcinosarcoma contains an overtly malignant epithelial component.
- Evaluate both cytologic atypia and tissue architecture; Not merely gland presence.

Contrast with pure leiomyosarcoma

Finding	Carcinosarcoma	Leiomyosarcoma
Epithelial carcinoma	Required	Not a constituent component
Mesenchymal tumor	Part of biphasic cancer	Primary smooth-muscle malignancy
Clonal model	Carcinoma-related shared drivers	Distinct uterine muscle-tumor category
Diagnostic focus	Document both malignant components	Smooth-muscle malignant criteria

Contrast with endometrial stromal sarcoma

Finding	Carcinosarcoma	Endometrial stromal sarcoma
Malignant epithelial element	Present	Not defining
Genetic framing	Carcinoma-like drivers	Fusion-associated subtypes described
Pathologic classification	Biphasic tumor	Pure stromal neoplasm
Pitfall	Sarcoma-rich biopsy	Missing carcinoma if poorly sampled

High-grade carcinoma can mimic a biphasic tumor

- A high-grade carcinoma can show a spindle-cell or undifferentiated area.
- Diagnosis rests on demonstrating a genuine malignant mesenchymal component.
- Immunostains can support interpretation but do not replace morphology.

Diagnostic matrix: Inspect both compartments

Diagnosis	Epithelium	Mesenchyme
Carcinosarcoma	Malignant	Malignant
Adenosarcoma	Benign (usually)	Malignant
Pure uterine sarcoma	Not malignant component	Malignant


Immunohistochemistry: Use as an adjunct

- Broad-spectrum cytokeratins can help identify carcinomatous elements.
- Expression may overlap; Staining patterns alone are not absolutely specific.
- Demonstration of both malignant morphologies remains the diagnostic anchor.

Markers for a specific heterologous component

- Myogenin or MyoD1 can support rhabdomyoblastic differentiation.
- Select lineage-specific studies for a defined morphologic question.
- Do not label all sarcomatous components “rhabdomyosarcoma” from nonspecific staining.

A practical tissue-based diagnostic sequence



A conceptual workflow synthesized and specialist differential-diagnosis sources.

FIGO 2023 explicitly treats carcinosarcoma as aggressive

- In the 2023 FIGO endometrial system, carcinosarcoma is an aggressive histologic type.
- The same anatomic extent can receive a different substage from low-grade endometrioid carcinoma.
- Do not assign 2023 substages using an older simplified stage table.

FIGO 2023: Stage IC concept

Histologic requirement

- Aggressive histologic type
- Includes carcinosarcoma

Anatomic requirement

- Confined to a polyp or the endometrium
- No myometrial invasion

Stage IC applies in this specified 2023 histology/anatomy scenario; Molecular modifiers may alter final stage.

FIGO 2023: Stage IIC concept

Histologic requirement

- Aggressive histologic type
- Includes carcinosarcoma

Anatomic requirement

- Any myometrial invasion
- Without findings requiring higher stage

Any myometrial invasion places an aggressive histotype in IIC in the morphology-based 2023 scheme.

Beyond the uterus: Regional and distant spread

- FIGO stage III covers local or regional extension beyond the uterus.
- FIGO stage IV includes advanced mucosal, extrapelvic peritoneal, or distant spread.
- Lymph-node and extrauterine-site findings require specific documentation.

2023 FIGO molecular modifiers need attention

- The 2023 staging framework encourages molecular characterization.
- Certain early-stage tumors can be upstaged or downstaged by molecular subtype.
- Avoid treating TP53 immunostaining alone as a complete molecular classification.

Case 1: A polypoid tumor with mixed malignancy

Teaching vignette (fictional)

- Postmenopausal bleeding.
- Hysterectomy shows a bulky endometrial polypoid tumor.
- Microscopy shows overtly malignant glands and malignant spindle-cell areas.

Which two morphologic components establish the core diagnosis?

Case 1: Establish the biphasic diagnosis

Interpretation

- Carcinomatous epithelium: Malignant gland-forming component.
- Sarcomatous mesenchyme: Malignant spindle-cell component.
- The combination supports uterine carcinosarcoma.

The polypoid configuration does not make the lesion a benign polyp.

Case 2: Benign glands with malignant stroma

Teaching vignette (fictional)

- Large endometrial polypoid mass.
- Glands appear benign despite distorted architecture.
- Intervening stroma is malignant.

Which biphasic tumor is favored over carcinosarcoma?

Case 2: Favor adenosarcoma

Interpretation

- Adenosarcoma: Benign epithelial glands with malignant stroma.
- Carcinosarcoma requires a malignant epithelial component.
- Review extensive sampling if any high-grade carcinoma appears elsewhere.

Distinguish gland presence from gland malignancy.

Case 3: An epithelial-only nodal metastasis

Teaching vignette (fictional)

- Uterine tumor is biphasic.
- Regional node contains only morphologically malignant epithelium.
- No sarcomatous component is identified in that node.

Does this contradict the uterine carcinosarcoma diagnosis?

Case 3: Metastasis may contain carcinoma alone

Interpretation

- No. Epithelial-only metastatic deposits as usual.
- A metastatic site need not mirror primary biphasic composition.
- Correlate with the fully characterized uterine primary.

Epithelial-only metastatic pattern is compatible with carcinosarcoma.

Case 4: Re-evaluate staging assumptions

Teaching vignette (fictional)

- Confirmed uterine carcinosarcoma.
- Tumor invades the myometrium; No extrauterine extension reported.
- Molecular classification is not yet available.

What is the morphology-based FIGO 2023 stage designation?

Case 4: FIGO 2023 and invasion

Interpretation

- Carcinosarcoma is designated an aggressive histologic type.
- Any myometrial invasion falls under stage IIC in the morphology-based 2023 system.
- Record molecular testing and any additional sites before finalizing staging.

This differs from simplified historical Stage I terminology.

Minimum information for a useful pathology report

- Identify both malignant components and specify heterologous elements if present.
- Document myometrial invasion and any extrauterine or nodal tumor.
- Integrate the appropriate FIGO staging framework with available molecular data.
- State limitations if only a small sample is examined.

Synthesis: Morphology → lineage → prognosis

Biphasic morphology



**Shared carcinoma-like
molecular biology**



**Invasion and stage govern
outcome**

Heterologous differentiation adds adverse prognostic information in the source.

Five high-value distinctions

- Carcinosarcoma has two malignant components, unlike adenosarcoma.
- Its paired components share driver mutations, supporting a single founder clone.
- Sarcomatous transformation mechanism remains incompletely explained.
- Metastatic deposits may show only carcinoma.
- Stage/depth dominate prognosis; Heterologous elements confer added risk.

Primary sources and supplementary verification

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026), Chapter 22, pp. 915–922.

Berek JS et al. FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 2023;34:e85.

McCluggage WG. A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus. Mod Pathol. 2016;29:S78–S91.

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations (2018).